Sanofi Expects Strong Earnings Growth This Year, Plans $5.2 Billion Buyback
The pharmaceutical company forecasts business earnings per share growth at a low double-digit percentage and plans to launch a $5.2 billion share buyback.
Sanofi plans 5 billion euro buyback, sees higher profit growth
SANOFI said it will repurchase five billion euros (S$7 billion) of stock and grow profits more quickly this year as the drugmaker pivots away from consumer health to focus on fast-growing drugs such as its respiratory syncytial virus (RSV) shot.
Sanofi Expected to Report Lower Sales, Profit; Size of Buyback in Focus -- Earnings Preview
BUSINESS OPERATING PROFIT FORECAST: Business operating profit--one of the company's preferred metrics, which strips out exceptional items--is forecast at 2.08 billion euros, according to the Vara Research consensus. Sanofi reported a business operating profit of 2.58 billion euros in the year-earlier period.
Sanofi Stock: €5 Billion Buyback Amid Strong Growth
Looking ahead, Sanofi has announced an ambitious share buyback program worth 5 billion euros for 2025, signaling strong confidence in its future prospects. The company projects mid to high single-digit revenue growth and anticipates low double-digit growth in adjusted earnings per share.
Sanofi Plans €5 Billion Buyback, Sees Higher Profit Growth
Sanofi said it will repurchase €5 billion ($5.2 billion) of stock and grow profits faster this year as the drugmaker pivots away from consumer health to focus on fast-growing drugs like its RSV shot.
Time To Be Bullish On Sanofi Ahead Of Its Earnings
Dupixent continues leading among Sanofi’s portfolio, and it’s poised for up to $20 billion in peak sales. Read my SNY ...
Sanofi reports Q4 IRFS EPS EUR 0.54
Reports Business EPS of EUR 1.31, down 11.0% at CER and down 14.9% reported. Reports Q4 IRFS net sales EUR 10.56B, up 9.1% reported and up ...
The Financial Express11d
Sanofi to increase competition in atopic dermatitis market after Dupixent’s success
The collaboration between Sanofi and Kymera Therapeutics on SAR444656 may represent a significant opportunity for competition ...
Healio3d
Dupilumab does not desensitize children with peanut allergy
Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents with peanut ...
Sanofi Q4 Business Net Income Declines; Net Sales Up 10.3% At CER
Sanofi (SNYNF, SNY) reported fourth quarter net income from continuing operations of 880 million euros compared to a loss of 119 ...
Sanofi: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025
Sanofi: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025 Paris, January 30, 2025 Q4: sales growth of 10.3% at CER1 and business EPS2 ...
Sanofi to increase competition in atopic dermatitis market after Dupixent success
Within the atopic dermatitis (AD) field, Sanofi has been developing the IRAK4 degrader SAR444656 (KT-474) in collaboration ...